• news.cision.com/
  • RhoVac/
  • RhoVac's  attending investor relation events and partnering meetings during October - November 2019

RhoVac's  attending investor relation events and partnering meetings during October - November 2019

Report this content

RhoVac AB ("RhoVac") participates in shareholder events in Sweden and international partnering meetings during October - November 2019.

Anders Månsson, CEO, will meet shareholders and present the company on the following occasions in Sweden:

• Sedermeradagen in Gothenburg, 4th October 2019. Registration can be made here.

• BioStock Summit at Medicon Village in Lund, 24th October. You can register here.

• Sedermeradagen in Stockholm, 18th November, and registration can be made here.

The company will also attend the Swedish Chamber of Commerce in New York's Innovate'46 event, 16th October, and at Bio-Europe in Hamburg (11-13th November), where approximately 1500 different companies, academic institutions and other related organizations from over 55 countries will also be present. 

For further information, please contact:

Anders Månsson – CEO, RhoVac AB

Phone number: +46 73-751 72 78

E-mail: info@rhovac.com

About RhoVac AB

RhoVac was established as a private company in Denmark in 2007. Under this company, the basic development steps for the drug candidate RV001 were undertaken. In 2015 the Swedish RhoVac AB was formed, which is now headquartered and in 2016 the company was listed on the then Aktietorget in Sweden (now Spotlight Stock Market). RhoVac has now passed the early stages of development. In 2018, the first clinical trial (phase I / II) was completed in prostate cancer, demonstrating that RV001 has good safety and is well tolerated, and that the drug provides the expected immune response that will exert its effect on the cancer cells. The strong immune response has also been shown to last over time. Therefore, RhoVac is immediately launching a major Phase IIb clinical trial that will include at least 175 prostate cancer patients. The study, which is expected to be completed in 2021, is designed to show, with statistical significance, the effect of RV001 in preventing disease progression in prostate cancer after surgery or radiation to the primary tumor. RhoVac is listed on Spotlight, Sweden, a Multilateral Trading Facility (MTF) since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com


Documents & Links